PetVivo Holdings, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $31.0M
- Price
- $0.8179
- % Change (Daily % change from the live per-ticker quote feed.)
- 0.00%
- Volume
- 58.5K
About
PetVivo Holdings, Inc. operates as a biomedical technology firm, specializing in the invention, commercialization, and licensing of advanced medical devices and biomaterials intended to treat a variety of ailments and diseases affecting animals. Its flagship product is Spryng, an intra-articular injection administered by veterinarians to effectively alleviate lameness and joint conditions, such as osteoarthritis, in canines and equines. The company's development pipeline further includes seventeen therapeutic devices poised for both veterinary and human clinical applications. Founded in 2009, PetVivo Holdings, Inc. maintains its corporate headquarters in Minneapolis, Minnesota.
Quick stats
Shares outstanding38.0M
Computed float33.6M
Float / shares88.4%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001512922
Websitehttps://www.petvivo.com
AI Summary
AI-generated1/22
minorneutralboard change
Michael Handley Joins PetVivo Holdings, Inc. Board of Directors
PetVivo Holdings appointed life sciences executive Michael K. Handley to its Board of Directors, effective September 22, 2026.
Handley brings 25+ years across biotech, pharma and medical devices, having raised more than $700 million in capital and contributed to transactions exceeding $4 billion in aggregate value.
He fills the vacancy left by Joseph Jasper's resignation the same day; the board remains at six members.
Red flags
- director resignation (Joseph Jasper) coinciding with new appointment